Russian Journal of Clinical Ophthalmology
ISSN 2311-7729 (Print), 2619-1571 (Online)

Effectiveness and tolerability of the combined use of anti-VEGF agents in clinical practice

VAK

Scopus

E-libraryDimensions

russian citation indexULRICHS

roaddoaj

ebscoРГБ

CyberleninkaGoogle Scholar

Open accessCrossrefAntiplagiat

RMJ.ru

Impact factor - 0,760*

* Impact factor according to the SCIENCE INDEX 2022



DOI: 10.32364/2311-7729-2020-20-4-209-215

A.V. Kuroyedov1,2, O.V. Gapon’ko1,2, V.V. Gorodnichiy1, S.V. Diordiychuk1, I.V. Kondrakova1, N.M. Sol’nov1, N.E. Fomin1,2

1P.V. Mandryka Military Clinical Hospital, Moscow, Russian Federation

2Pirogov Russian National Research Medical University, Moscow, Russian Federation

Aim: to assess the effectiveness and tolerability of anti-VEGF agents, aflibercept (2.0 mg) and ranibizumab (0.5 mg), in the combined treatment for wet age-related macular degeneration (AMD) in routine clinical practice.

Patients and Methods: 55 patients (65 eyes) with the late stage of wet AMD were divided into two groups. Group 1 included 32 eyes with classic choroidal neovascularization (CNV) and group 2 included 33 eyes with occult CNV. Best-corrected visual acuity (BCVA), intraocular pressure, and retinal nerve fiber layer (RNFL) thickness were measured. These parameters were compared at different time points during the treatment.

Results: overall AMD duration (January 2019) was 36 (19; 47) months being 30 (12; 44) months in group 1 and 36 (23; 48) months in group 2 (р>0.05). The first intravitreal administration of an anti-VEGF drug was performed 7.5 (3.5; 9.5) months after AMD diagnosis in group 1 and 7 (3; 11) months after AMD diagnosis in group 2. Significant differences in intragroup intervals were revealed between various follow-up periods. More differences were identified for the intervals between intravitreal administrations in group 2. Baseline and final BCVA during the entire follow-up which was 29.5 (19.5; 38) months in group 1 and 28 (25; 44) months in group 2 demonstrated neither intragroup nor intergroup differences (р>0.05).

Conclusion: our management strategy for wet AMD is somewhat different from conventional guidelines. However, it has no significant impact on visual acuity during the follow-up.

Keywords: age-related macular degeneration, anti-VEGF drugs, intravitreal administration, IOP level, aflibercept, ranibizumab.

For citation: Kuroyedov A.V., Gapon’ko O.V., Gorodnichiy V.V. et al. Effectiveness and tolerability of the combined use of anti-VEGF agents in clinical practice. Russian Journal of Clinical Ophthalmology. 2020;20(4):209–215. DOI: 10.32364/2311-7729-2020-20-4-209-215.



About the authors:

1,2Aleksandr V. Kuroyedov — Doct. of Sci. (Med.), Professor of the Department of Ophthalmology, Head of the Division of Ophthalmology, ORCID iD 0000-0001-9606-0566;

1,2Olesya V. Gapon’ko — Cand. of Sci. (Med.), ophthalmologist of the Division of Ophthalmology, assistant of the Department of Ophthalmology, ORCID iD 0000-0001-5893-7371;

1Vitaliy V. Gorodnichiy — ophthalmologist of the Division of Ophthalmology, ORCID iD 0000-0002-7276-5753;

1Svetlana V. Diordiychuk — ophthalmologist of the Consultative Division, ORCID iD 0000-0002-0668-8171;

1Irina V. Kondrakova — ophthalmologist of the Consultative Division, ORCID iD 0000-0002-8394-0094;

1Nikolay M. Sol’nov — Cand. of Sci. (Med.), ophthalmologist, ORCID iD 0000-0003-3970-039X;

1,2Nikolay E. Fomin — ophthalmologist of the Consultative Division, assistant of the Department of Ophthalmology, ORCID iD 0000-0001-9516-7396.

1P.V. Mandryka Military Clinical Hospital, 8A, Bolshaya Olenya str., Moscow, 107014, Russian Federation.

2Pirogov Russian National Research Medical University, 1, Ostrovityanov str., Moscow, 117437, Russian Federation.


Contact information: Nikolay E. Fomin, e-mail: nikolay.fomin2608@yandex.ru. Financial Disclosure: no authors have a financial or property interest in any material or method mentioned. There is no conflict of interests. Received 21.02.2020. 

References

1. Budzinskaya M.V. Age-related macular degeneration. Vestnik oftal’mologii. 2014;130(6):56–61 (in Russ.).

2. Bobykin E.V. Anti-angiogenic therapy for treatment of macular disorders in ophthalmology. Literature review. Practical Medicine. 2018;16(5):104–111 (in Russ.). DOI: 10.32000/2072-1757-2018-16-5-104-111.

3. Astakhov Yu.S., Nechiporenko P.A. Dosing regimens of angiogenesis inhibitors in the treatment of neovascular age-related macular degeneration patients. Ophthalmology Journal. 2019;12(2):47–56 (in Russ.). DOI: 10.17816/OV12247-56.

4. Khanna S., Komati R., Eichenbaum D.A. et al. Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review. BMJ Open Ophthalmology. 2019;4:000398. DOI: 10.1136/ bmjophth-2019-000398.

5. Ross A.H., Downey L., Devonport H. et al. Recommendations by a UK expert panel on an aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degeneration. Eye. Published online. 2020. DOI: 10.1038/s41433-019-0747-x.

6. Lanzetta P., Loewenstein A. Vision Academy Steering Committee. Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases. Graefes Arch Clin Exp Ophthalmol. 2017;255:1259–1273. DOI: 10.1007/s00417-017-3647-4.

7. Kim L.N., Mehta H., Barthelmes D. et al. Meta-analysis of real-world outcomes of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration. Retina. 2016;36:1418–1431. DOI: 10.1097/IAE.0000000000001142.

8. Oubraham H., Cohen S.Y., Samimi S. et al. Inject and extend dosing versus dosing as needed; a comparative retrospective study of ranibizumab in exudative age-related macular degeneration. Retina. 2011;31(1):26–30. DOI: 10.1097/IAE.0b013e3181de5609.

9. Lee A.Y., Lee C.S., Egan C.A. et al. UK AMD/DR EMR Report IX: comparative effectiveness of predominantly as needed (PRN) ranibizumab versus continuous aflibercept in UK clinical practice. Br J Ophthalmol. 2017;101(12):1683–1688. DOI: 10.1136/bjophthalmol-2016-309818.

10. Wong I., Danny N., Fung N. et al. Treat-and-extend regimen for management of neovascular age-related macular degeneration: recommendations from the Hong Kong Retina Expert Panel. Hong Kong J Ophthalmol. 2019;23(1):15–19. DOI: 12809/hkjo-v23n1-T&E.

11. Kertes P.J., Galic I.J., Greve M. et al. Efficacy of a Treat-and-Extend Regimen With Ranibizumab in Patients With Neovascular Age-Related Macular Disease: A Randomized Clinical Trial. JAMA Ophthalmol. 2020;138(3):244–250. DOI: 10.1001/jamaophthalmol.2019.5540.

12. Ohji M., Takahashi K., Okada A.A. et al. Efficacy and Safety of Intravitreal Aflibercept Treat- and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR. A Randomized Controlled Trial. Adv Ther. 2020;37:1173–1187. DOI: 10.1007/s12325-020-01236-x.

13. García-Layana A., García-Arumı J., Figueroa M.S. et al. Management of Wet Age-Related Macular Degeneration in Spain: Challenges for Treat and Extend Implementation in Routine Clinical Practice. Hindawi J Ophthalmol. Published online. 2019. DOI: 10.1155/2019/9821509.

14. Wong W.L., Su X., Li X. et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. The Lancet Global Health. 2014;2(2):106–116. DOI: 10.1016/S2214-109X (13) 70145-1.

15. Taskintuna I., Elsayed M.A., Schatz P. Update on clinical trials in dry Age-related macular degeneration. Middle East Afr J Ophthalmol. 2016;23:13–26. DOI: 10.4103/0974-9233.173134.

16. Age-Related Eye Disease Study Research Group A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001;119(10):1417–1436. DOI: 10.1001/archopht.119.10.1417.

17. Age-Related Eye Disease Study Recearch Group. A simplified severity scale for age-related macular degeneration. Arch Ophthalmol. 2005;123(11):1570–1574. DOI: 10.1001/archopht.123.11.1484.

18. Balashevich L.I., Izmailov A.S., Ulitina A.Y. A modified clasification of clinical age — related macular degeneration. Ophthalmology Journal. 2011;4(4):41–47 (in Russ.).

19. Brown D.M., Kaiser P.K., Michels M. et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. New Engl J Med. 2006;355(14):1432–1444. DOI: 10.1056/nejmoa062655.

20. Pershin B.S., Kozlova I.V., Ermolaev A.P. Experimental evaluation of correlation between intraocular pressure fluctuation and hemodynamic indices of the eye after intravitreous injection. National J Glaucoma. 2012;1:16–19 (in Russ.).

21. Avetisov S.É., Erichev V.P., Budzinskaia M.V. et. al. Age-related Macular Degeneration and Glaucoma: Intraocular Pressure Monitoring after Intravitreal Injections. Vestnik Oftalmologii. 2012;128(6):3–5 (in Russ.).

22. Loskutov I.A. Results of Lucentis use as a routine practice in wet age-related macular degeneration patients. Ophthalmology Journal. 2014;1:47–57 (in Russ.). DOI: 10.17816/OV2014147-57.

23. Bubnova I.A., Yulova A.G. Optic nerve head changes with acute IOP elevation after intravitreal injections. National J Glaucoma. 2016;15(2):54–60 (in Russ.).

24. Bubnova I.A., Kurguzova A.G. Changes in intraocular pressure after intravitreal injections. Vestnik Oftalmologii. 2018;134(4):47–51 (in Russ.). DOI: 10.17116/oftalma201813404147.

25. Kuroyedov A.V., Zakharova M.A., Gaponko O.V., Gorodnichy V.V. The effect of intravitreal injection of anti-VEGF drugs on the ophthalmotonus values in patients with classic and occult choroidal neovascularization. RMJ. Clinical ophthalmology. 2018;2:102–106 (in Russ.). DOI: 10.2189/2311-7729-2018-18-2-102-106.

26. Budzinskaya M.V., Bubnova I.A., Kurguzova A.G., Fettser E.I. Structural changes in the ocular anterior segment against elevation of intraocular pressure after repeated intravitreal injections. Vestnik Oftalmologii. 2018;134(5):156–161 (in Russ.). DOI: 10.17116/oftalma2018134051156.

27. Vitale S., Agrón E., Clemons T.E. et al. Association of 2-Year Progression Along the AREDS AMD Scale and Development of Late Age-Related Macular Degeneration or Loss of Visual Acuity: AREDS Report 22. JAMA Ophthalmol. 2020;138(6):610–617. DOI: 10.1001/jamaophthalmol.2020.0824.

28. Nebbioso M., Lambiase A., Cerini A. et al. Therapeutic Approaches with Intravitreal Injections in Geographic Atrophy Secondary to Age-Related Macular Degeneration: Current Drugs and Potential Molecules. Int. J. Mol. Sci. 2019;20:1693. DOI: 10.3390/ijms20071693.





License Creative Commons
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Previous article
Next article

Register now and get access to useful services:
  • Загрузка полнотекстовых версий журналов (PDF)
  • Медицинские калькуляторы
  • Список избранных статей по Вашей специальности
  • Видеоконференции и многое другое

С нами уже 50 000 врачей из различных областей.
Присоединяйтесь!
[Error] 
Call to undefined function get_registration_form_description_popup() (0)
/home/c/cb72209/clinopht.com/public_html/en/include/reg_form.php:89
#0: include
	/home/c/cb72209/clinopht.com/public_html/bitrix/modules/main/classes/general/main.php:1419
#1: CAllMain->IncludeFile(string)
	/home/c/cb72209/clinopht.com/public_html/local/templates/.default/include/cl-footer.php:217
#2: include_once(string)
	/home/c/cb72209/clinopht.com/public_html/local/templates/cl_inner_sidebar_en/footer.php:11
#3: include_once(string)
	/home/c/cb72209/clinopht.com/public_html/bitrix/modules/main/include/epilog_before.php:93
#4: require(string)
	/home/c/cb72209/clinopht.com/public_html/bitrix/modules/main/include/epilog.php:2
#5: require_once(string)
	/home/c/cb72209/clinopht.com/public_html/bitrix/footer.php:4
#6: require(string)
	/home/c/cb72209/clinopht.com/public_html/en/articles/index.php:150
#7: include_once(string)
	/home/c/cb72209/clinopht.com/public_html/bitrix/modules/main/include/urlrewrite.php:184
#8: include_once(string)
	/home/c/cb72209/clinopht.com/public_html/bitrix/urlrewrite.php:2
----------